Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation: A Single Institute Experience with Focus on Epstein-Barr Virus Status
P. Zhang,1 R. King,1 K. Ristow,2 L. Cornell,1 F. Cosio,3 T. Habermann,2 M. Alexander.1
1Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
2Divsion of Hematology and Oncology, Mayo Clinic, Rochester, MN
3Divsion of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.
Meeting: 2018 American Transplant Congress
Abstract number: B361
Keywords: Epstein-Barr virus (EBV), Kidney transplantation, Post-transplant lymphoproliferative disorder (PTLD)
Session Information
Session Name: Poster Session B: PTLD/Malignancies: All Topics
Session Type: Poster Session
Date: Sunday, June 3, 2018
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall 4EF
Background: Comparing to other types of solid organ transplant, the Post-Transplant Lymphopro- liferative Disorder (PTLD) in kidney transplant recipients (KTRs) is relatively rare. Due to the rarity, the results obtained from previous cohorts are likely obscured by the heterogeneous nature of PTLD. This study reports PTLD in KTRs treated in a single institute with a focus on Epstein-Barr Virus (EBV)-status.
Methods: Adult PTLD cases in KTRs treated at Mayo Clinic Rochester, were retrospectively identified from our database for the years 1993-2016. The clinical features including occurrence of PTLD, type of PTLD, EBV status, site of organ involvement, response to treatment and survival record were reviewed and analyzed. Clinical characteristics were compared using chi-square (categorical) and student's t-test (continuous). Overall survival was measured as time from diagnosis to last known alive date or date of death and was analyzed using the log-rank test.
Results: Sixty-four adult PTLD patients in KTRs treated at Mayo Clinic Rochester were identified, including 36 EBV-related and 28 non-EBV-related. EBV-related PTLD patients were diagnosed earlier than non-EBV-related (59.5 vs 114.7 months; p=0.02), were less likely to develop T-cell lymphoma (0 vs. 14%; p=0.03) and have more gastrointestinal tract involvement (19.4 vs. 46.4%; p=0.02). Other clinical features including the incidence of B-cell lymphoproliferative disorders and treatment response were not significantly different between these two groups. The median overall survival (OS) was not significantly different between EBV related and non-related groups (p=0.49).
Conclusion: EBV-related and non-EBV-related PTLDs in KTRs may be two distinct entities due to their differences on the timing of diagnosis, incidence of T-cell lymphoma and organ involvement. However, the occurrence of various types of B-cell lymphoproliferative disorder and treatment responses are similar in these two groups.
CITATION INFORMATION: Zhang P., King R., Ristow K., Cornell L., Cosio F., Habermann T., Alexander M. Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation: A Single Institute Experience with Focus on Epstein-Barr Virus Status Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Zhang P, King R, Ristow K, Cornell L, Cosio F, Habermann T, Alexander M. Post-Transplant Lymphoproliferative Disorder after Kidney Transplantation: A Single Institute Experience with Focus on Epstein-Barr Virus Status [abstract]. https://atcmeetingabstracts.com/abstract/post-transplant-lymphoproliferative-disorder-after-kidney-transplantation-a-single-institute-experience-with-focus-on-epstein-barr-virus-status/. Accessed October 11, 2024.« Back to 2018 American Transplant Congress